This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Navidea Biopharmaceuticals To Co-Sponsor Alzheimer’s Imaging Consortium At Alzheimer’s Association International Conference

Stocks in this article: NAVB

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it will co-sponsor the 2013 Alzheimer’s Imaging Consortium on July 13, 2013. The full-day event features leading international experts and will be chaired by Drs. Gil Rabinovici, University of California, San Francisco, United States, and Christopher Rowe, Austin Health, Melbourne, Australia. The Consortium is part of the Alzheimer’s Association International Conference (AAIC), being held July 13 – 18, 2013, in Boston, Mass. The annual AAIC is attended by leaders in dementia research and medicine from around the globe, and is the largest conference of its kind in the world.

“We are honored that Navidea is supporting the Alzheimer’s Imaging Consortium, because education and peer-to-peer scientific dialogue are fundamental to advancing important clinical knowledge that can lead to more informed diagnosis and improved care for patients with Alzheimer’s disease and other dementias,” said Dr. Connie Reininger, Navidea’s Senior Vice President and Chief Medical Officer.

“Navidea’s commitment to advancing precision diagnostics encompasses our neuroimaging candidates NAV4694, in development for use as an aid in the diagnosis of Alzheimer’s disease and potentially Mild Cognitive Impairment; and NAV5001, which we are developing to aid in the evaluation of patients who may have dementia with Lewy Bodies, in addition to its benefits in the diagnosis of Parkinson’s Disease,” commented Dr. Mark Pykett, Chief Executive Officer of Navidea.

The Alzheimer's Imaging Consortium will consist of invited speakers, as well as oral and poster presentations from submitted abstracts. Leading imaging and non-imaging researchers from around the world will discuss topics such as:

  • Early and differential diagnosis and the proposal for new criteria;
  • Tracking progression and evaluating treatments;
  • Asymptomatic stages of Alzheimer's and normal brain aging;
  • Cognitive and basic neuroscientific studies: animal imaging, imaging and genetics;
  • Multi-modality imaging studies and new imaging methods; and
  • The latest developments on other dementias such as Lewy body disease and vascular diseases.

About NAV4694

NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate intended for use in Positron Emission Tomography (PET) imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer’s disease (AD). NAV4694 binds to β-amyloid deposits in the brain that can then be imaged in scans. β-amyloid plaque pathology is widely used in the diagnosis of AD. The ability of NAV4694 imaging to display amyloid plaque pathology may enable earlier identification of AD and improve monitoring of disease progression and interpretation of brain scan images. Navidea has an ongoing NAV4694 Phase 2b trial in Mild Cognitive Impairment and a Phase 3 program for NAV4694 in AD.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs